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Background. In 2016, the first global viral hepatitis elimination targets were endorsed. An estimated one-third of the world’s 
population of individuals with chronic hepatitis B virus (HBV) infection live in China and liver cancer is the sixth leading cause of 
mortality, but coverage of first-line antiviral treatment was low. In 2015, China was one of the first countries to initiate a consultative 
process for a renewed approach to viral hepatitis. We present the investment case for the scale-up of a comprehensive package of 
HBV interventions.
Methods. A dynamic simulation model of HBV was developed and used to simulate the Chinese HBV epidemic. We evaluated 
the impact, costs, and return on investment of a comprehensive package of prevention and treatment interventions from a societal 
perspective, incorporating costs of management of end-stage liver disease and lost productivity costs.
Results. Despite the successes of historical vaccination scale-up since 1992, there will be a projected 60 million people still living 
with HBV in 2030 and 10 million HBV-related deaths, including 5.7 million HBV-related cancer deaths between 2015 and 2030. This 
could be reduced by 2.1 million by highly active case-finding and optimal antiviral treatment regimens. The package of interventions 
is likely to have a positive return on investment to society of US$1.57 per US dollar invested.
Conclusions. Increases in HBV-related deaths for the next few decades pose a major public health threat in China. Active case-
finding and access to optimal antiviral treatment are required to mitigate this risk. This investment case approach provides a real-
world example of how applied modeling can support national dialog and inform policy planning.
Keywords.  hepatitis B; antiviral treatment; investment case; China; modeling.
In 2016, the World Health Assembly endorsed the first global 
viral hepatitis targets, calling for elimination of viral hepatitis 
as a public health threat by 2030. Ahead of the official adoption 
of these global targets, China led the way in initiating an invest-
ment case to inform the development of a national strategy for 
combating viral hepatitis in 2015. It is estimated that one-third 
of the world’s population of individuals with chronic hepatitis 
B virus (HBV) infection live in China where liver cancer is the 
sixth leading cause of mortality [1–3].
China has made substantial efforts to reduce HBV trans-
mission, including early introduction of infant vaccination in 
1992, subsequent integration into the Expanded Program on 
Immunization in 2002 and abolishment of patient copayments 
for vaccines in 2005, supported through combined domestic 
and Global Vaccine Alliance funding [4]. Furthermore, cov-
erage of timely birth-dose vaccine administration was strength-
ened by promoting birthing within healthcare facilities as part 
of a rural reform policy [5]. China has therefore witnessed a 
97% reduction in hepatitis B surface antigen (HBsAg) preva-
lence in under-5-year-olds between 1992 and 2014 [6].
Despite these significant prevention efforts, the country con-
tinues to face a high burden of adult HBV, with nearly 90 mil-
lion people estimated to have chronic HBV (although burden 
estimates from different sources   are variable) [2, 7–9] from 
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historical transmission. There are nearly 400 000 annual liver 
cancer deaths [10, 11]. When the World Health Organization 
(WHO) targets were launched in 2016, treatment uptake was 
low and most patients with HBV incurred significant out-of-
pocket expenses, as there was limited reimbursement for HBV 
antiviral therapy. This often leads to high, or even catastrophic, 
health expenditures associated with treatment [12–15].
Recognizing this high burden of disease and the need to 
strengthen national viral hepatitis policies, a consultative pro-
cess was initiated in 2015 by the Chinese Center for Disease 
Control and Prevention (China CDC) and the WHO, in collab-
oration with key national and international stakeholders. The 
aim of this study was to make the case for investment for a com-
prehensive package of interventions against HBV that would 
deliver substantial health and economic benefits in China. This 
study was part of the evidence presented as policy briefs to the 
government. We will discuss lessons learned for investment 
case methodology for viral hepatitis and how applied modeling 
can be used to translate policy into practice.
METHODS
Overview
The investment case was performed collaboratively between re-
searchers at Imperial College London (United Kingdom), the 
WHO’s China Office, China CDC, and other key stakeholders 
in China.
We developed a mathematical model to address the priority 
policy questions under consideration: to evaluate the impact, 
costs, and return on investment (ROI) of a comprehensive scale-up 
package of prevention and treatment interventions. The structure 
of the epidemiological model was based on a previously published 
dynamic transmission HBV model and has been described else-
where [16]. In brief, we used a simulation model of the hepatitis 
B epidemic, structured by age and sex and fitted to empirical data 
on HBsAg and hepatitis B e antigen (HBeAg) prevalence in 1992, 
2006, and 2014 [6, 17], and liver cancer mortality in 2012, with an 
HBV-related liver cancer population attributable fraction of 70% 
[18, 19]. The model incorporates demographic data, coverage of 
existing interventions [17, 20, 21], and assumptions about the nat-
ural history of HBV informed by literature review.
Intervention Scenarios
The model was used to make projections of the incidence of 
new chronic infections, prevalence, and deaths due to HBV 
under different intervention coverage scenarios (including a 
status quo scenario) (Table 1). The model was used iteratively to 
agree on final scenarios based on outcomes considered achiev-
able, adapted to the local setting and aligned with broader 
strategic goals.
In China, given the high historical coverage of infant and 
birth-dose vaccination and the use of HBIG, we considered a 
“Full Prevention” scenario as the scale-up to 100% coverage of 
infant vaccination and 100% coverage of Prevention of Mother-
to-Child Transmission (PMTCT) interventions (to include all 
available methods), recognizing that the exact method chosen 
to reach this coverage would need to be driven by further im-
plementation research and country-specific considerations on 
feasibility and cost-effectiveness.
We also considered 4 treatment scenarios, which were 
added to the “Full Prevention” scenario (Table 1). Within the 
existing healthcare structure, there are already patients who 
have been diagnosed with chronic hepatitis B (CHB) and 
treated suboptimally. Therefore, a scenario of treating those al-
ready in care, without extra active case-finding was modeled 
(“Treatment for Those Already in Care”). We then considered a 
scenario where case-finding was increased to 20% and antiviral 
treatment was given to all eligible patients, as recommended by 
Table 1. Intervention Scenarios Modeled
Description
Infant  
Vaccination, %
Birth-dose 
Vaccination, 
%
HBIG,a 
%
Peripartum 
Antivirals,a %
Treatment  
Eligibility
New diagnosis, 
%
Linkage to Care 
and Retention, %
Status quo Continues at current baseline levels
Full prevention 100 100 100 100 n/a … …
Full prevention + treat 
those already in careb
100 100 100 100 Local guidelines 0 …
Full prevention + case 
finding 20% and treat 
all eligible
100 100 100 100 Local guidelines 20 90, 90
Full prevention + case 
finding 20% and treat 
cirrhosis only
100 100 100 100 Cirrhotics only 20 90, 90
Comprehensive package 
of public health inter-
ventions
100 100 100 100 Local guidelines 50 90, 90
Abbreviations: HBIG, hepatitis B immunoglobulin; HBV, hepatitis B virus; n/a, not applicable.
aOf those requiring intervention. The percentage of case finding represents the percentage of new cases diagnosed in each scenario.
bTreatment of those in care, assumes that 3.8% of all persons with HBV are already in care.
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contemporaneously available international guidelines (“Case 
Finding 20% & Treat All Eligible”). An additional scenario in-
cluded the impact of a disease prioritization strategy, where 
treatment was given only to those with cirrhosis (“Case Finding 
20% & Treat Cirrhosis Only”). The final scenario included the 
full suite of prevention interventions and high  and high cov-
erage  level of 50% case-finding and treatment of all those eli-
gible for treatment, which we refer to throughout this article as 
the “Comprehensive Package of Public Health Interventions.”
Economic Analysis
An overall societal perspective was taken for the anal-
ysis, incorporating both intervention and wider noninter-
vention costs, and co-financing strategies were evaluated. 
Nonintervention costs include health system and household 
costs associated with providing care to those with liver disease 
(also referred to as “care costs”) and the costs of premature death 
[14]. Costs of premature death were calculated based on the 
human capital approach [22] and quantified by the net present 
value of potential future earnings lost from the year of HBV-
related death up to 65 years of age. Average annual income was 
used to represent potential future earning losses, factoring in a 
5% national unemployment rate. Costs (presented in 2015 US 
dollars) were adjusted for inflation [23] and discounted at 3% 
per annum, in keeping with WHO guidelines [24] (Table 2). For 
the baseline analysis, the cost of tenofovir used was $290 per 
person-year (1800 renminbi [RMB]), which corresponded to the 
price of tenofovir contemporaneously available to the national 
human immunodeficiency virus (HIV) program in China.
The primary outcome measure was the ROI on the 
“Comprehensive Package of Public Health Interventions,” 
which we defined as the ratio between money defrayed in the 
collateral costs compared with a “status quo” projection to the 
money invested in the interventions.
Multivariate probabilistic sensitivity analysis was performed 
using cost parameter ranges of 0.5–2 times the default estimate. 
Sampling was performed using the Latin Hypercube method.
RESULTS
Epidemiological Projections
The fit between the modeled results and the data for HBsAg 
prevalence, HBeAg prevalence, and HBV-related cancer deaths 
can be seen in Figure 1; for the year 2015 this represents a mod-
eled baseline of 81 million persons living with chronic HBV 
infection, 54  000 new chronic infections, and 570  000 HBV-
related deaths.
At status quo levels of intervention coverage, the incidence of 
new chronic infections would fall from 6500 per year in 2030 to 
less than 500 per year in 2050 and the number of people living 
with HBV will decline from 60 million to 32 million over the 
same period (Supplementary Figure 1). This decline in inci-
dence and prevalence of chronic HBV at status quo levels is seen 
because coverage of prevention interventions has been strong 
in China and the cohort of those already infected with CHB 
are aging.
However, without a change in strategy, there will still be 60 
million people living with HBV in 2030 and the major public 
health threat will come from HBV-related deaths, which will 
continue to rise and are projected to be 680  000 annually in 
the year 2030. Without scale-up of treatment and continuing at 
status quo we project there to be 10 million HBV-related deaths 
cumulatively over 15 years (2015–2030), including 5.7 million 
HBV-related cancer deaths (Figure 2).
The scale-up of prevention efforts alone (“Full Prevention”), 
would avert 150 000 new chronic infections over 15 years com-
pared with the status quo. The main impact of the scale-up of 
case-finding and treatment strategies would be seen on HBV-
related mortality, which would yield the following 15-year 
HBV-related mortality benefits when compared with the status 
quo; “Treat Those Already in Care” would avert 162 000 deaths, 
“Case Finding 20% & Treat All Eligible” would avert 930 000 
deaths, “Case Finding 20% & Treat Cirrhosis Only” would avert 
706 000 deaths (Figure 2 and Supplementary Table 1).
The “Comprehensive Package of Public Health Interventions” 
has the highest impact and could avert nearly 160  000 fur-
ther new chronic infections and 2 million HBV-related deaths 
(985  000 of which will be cancer deaths) between 2015 and 
2030, compared with the status quo.
Economic Projections
For the comprehensive public health program, the total costs 
of the intervention components alone would be $2.6 billion (16 
billion RMB) in 2020, rising to $3.5 billion (22 billion RMB) in 
2030, and would have decreased to $1.8 billion (11 billion RMB) 
by 2050. Over 15 years, 97% of the cumulative costs would con-
sist of case-finding and treatment costs.
Accounting for the wider nonintervention costs, this com-
bined total is projected to be $23 billion (141 billion RMB) 
and $15 billion (92 billion RMB) at status quo, but $21 billion 
(130 billion RMB) and $13 billion (83 billion RMB) for the 
“Comprehensive Package of Public Health Interventions” in 
2020 and 2030, respectively (Figure 3A).
Cumulative costs of premature death are estimated to be $89 
billion (549 billion RMB) between 2015 and 2030 at status quo 
but reduced to $68 billion (423 billion RMB) with the compre-
hensive package, meaning that nearly $20 billion (126 billion 
RMB) of productivity losses would be averted. As the new inter-
ventions start to take effect, direct medical costs are also dis-
placed as fewer people are in late stages of disease.
Figure 3B shows how costs are partitioned between the different 
parties over time to fund a comprehensive package under the pro-
posed copayment scenario; government and insurance spending 
would increase by $0.09 billion (0.5 billion RMB) and $5.2 billion 
(32 billion RMB), respectively, in 2020 compared with the status 
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Table 2. Cost Parameters
Intervention Costs Component Price, USD Source and Comments
 Infant vaccination Unit cost (per dose) 0.63 China CDC
Delivery costs 0.81 China CDC
 Birth-dose vaccination Unit cost (per dose) 0.63 China CDC
Delivery cost 0.81 Assume same as infant vaccination
 HBIG Unit cost 16.13 CDC China
Delivery cost 1.61 Assume double cost of birth dose
 Peripartum antiviralsa Drug (tenofovir) 97 HIV price of tenofovir (4 months)
Delivery 142 Unpublished datab
 Getting someone into care Case finding 200 Assumption, based on HIV case- 
finding costs
Initial diagnostic eval-
uation
85 Unpublished datab
 Annual monitoring Yearly monitoring 114 Unpublished datab
 Antiviral therapy (annual) Lamivudine 748 Reform 2015
Tenofovir 290 Price of tenofovir available to HIV 
program in China (2015) [25]
Nonintervention costs (costs of care)c,d Component Stage of Disease Cost, USD
 Direct Direct medical   
 Annual Outpatient 
Cost
CHB 591e
CC 1128f
DC 1416
HCC 1251
 Annual Inpatient 
Cost
CHB 228
CC 302
DC 1426
HCC 4048
 Cost of medicines 
self-purchased
CHB 188e
CC 134e
DC 251
HCC 218
Direct nonmedical CHB 373
 CC 718
 DC 777
 HCC 567
 Indirect … CHB 256
CC 440
DC 741
HCC 531
Other economic parameters Estimate Source  
 National annual average income 1669 USD China Statistics Yearbook  
 Average age of ending contribution 
to GDP
65 years Assumption  
 National unemployment rate 5% World Bank  
 Discount rate: costs 3% WHO guidelines on economic evalua-
tion of cost-effectiveness [25]
 
 Discount rate: health benefits 3%  
 GDP per capita 7505 USD (2014) National Bureau of Statistics, 2014  
 Conversion rate 1 USD = 6.2 RMB OANDA  
 Inflation rate 3% World Bank  
Costs in this table are presented in USD (1 US$ = 6.2 RMB).
Abbreviations: CC, compensated cirrhosis; CDC, Center for Disease Control and Prevention; CHB, chronic hepatitis B; DC, decompensated cirrhosis; GDP, Gross Domestic Product; HBV, hep-
atitis B virus; HCC, hepatocellular carcinoma; HIV, human immunodeficiency virus; RMB, renminbi; OPD, outpatient department; USD, US dollars; WHO, World Health Organization.
aAssume 4 months of antiviral drug and 6 months of diagnostics.
bChina National Health Development and Research Center (Chang et al, manuscript under preparation—see Supplementary Appendix).
cSource: Hu et al [14]; only Beijing costs included.
dAssumed that 15% of patients with HBV will already be “in care.”
eAssumed that after the intervention, these were not included.
fAssumed that after the treatment intervention, these were halved.
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quo. Government spending will see the biggest relative increase in 
its projected spending, but this will be for a short period of time 
during the active case-finding. Conversely, costs to the patients 
and society would be $5.7 billion (35 billion RMB) and $1.3 bil-
lion (8 billion RMB) less, respectively, than at status quo. This con-
trasts sharply with the scenario in which patients would continue 
to pay out-of-pocket at contemporaneous costs for tenofovir for 
treatment of hepatitis (nearly $3000 per person per year), which 
would be 160% of average annual incomes, for medication alone.
Return on Investment From a Societal Perspective
Between 2015 and 2030, investing $42 billion (258 billion RMB) 
into a comprehensive package of interventions is projected to 
give an economic return of $65 billion (406 billion RMB) from 
an overall societal perspective. This would amount to an ROI 
of $1.57 per US dollar invested and could avert 2.1 million 
deaths by 2030. These economic returns are largely driven by 
the reduced costs of premature death (due to increased life ex-
pectancy and therefore increase in income generated) and the 
reduced medical costs of management of end-stage liver disease 
as less people are in late stages of disease (reduced care costs). 
Cumulatively, over 15  years, investing in the comprehensive 
package reduces economic losses due to premature death by 
30% and care costs by 23%.
Uncertainty around the cost estimates is represented in 
Supplementary Figure 2. Although exact quantifications about 
HBsAg Prevalence
China
0 5 10 15 20
Prevalence (%)
HBsAg (Women 5-10y)
HBsAg (Women 10-30y)
HBsAg (Women 30-59y)
HBsAg (Men 5-10y)
HBsAg (Men 10-30y)
HBsAg (Men 30-59y)
Model: 1992
Data: 1992
Model: 2006
Data: 2006
Model: 2014
Data: 2014
HBeAg Prevalence
0 20 40 60 80 100
Prevalence (%)
HBeAg (Women 0-10y)
HBeAg (Women 20-30y)
HBeAg (Women 30-40y)
HBeAg (Men 0-10y)
HBeAg (Men 20-30y)
HBeAg (Men 30-40y)
0-
14
15
-3
9
40
-4
4
45
-4
9
50
-5
4
55
-5
9
60
-6
4
65
-6
9
70
-7
4
75
+
Age-group
0
20
40
60
80
100
120
H
BV
 C
an
ce
r D
ea
th
s
/1
00
,0
00
Cancer Deaths: Women
Model
Data
0-
14
15
-3
9
40
-4
4
45
-4
9
50
-5
4
55
-5
9
60
-6
4
65
-6
9
70
-7
4
75
+
Age-group
0
50
100
150
200
250
H
BV
 C
an
ce
r D
ea
th
s
/1
00
,0
00
Cancer Deaths: Men
Model
Data
Figure 1. Panels representing the calibration of data against models for HBsAg prevalence, HBeAg prevalence, and cancer deaths. Abbreviations: HBeAg, hepatitis B e 
antigen; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus.
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the magnitude of benefits remain uncertain, the direction of the 
economic benefit is clear.
Figure 4 examines how variation in 2 of the most uncertain 
cost inputs, namely care costs and treatment costs, would affect 
whether the comprehensive package would provide a positive 
ROI. If our study has underestimated treatment costs, the com-
prehensive package is unlikely to provide a positive ROI.
DISCUSSION
Maintenance of prevention interventions against HBV infection are 
essential in China. However, the major public health impact now 
will come from averting HBV-related deaths. Without a scale-up of 
HBV testing and treatment, there will be 10 million HBV-related 
deaths, including 5.7 million HBV-related cancer deaths between 
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Figure 2. A, Impact of intervention scale-up on HBV. Panels representing HBsAg prevalence among 5-year-olds, number of people living with HBV, and HBV-related deaths. 
B, Cumulative 15-year impact on deaths and incidence in China. Abbreviations: HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus.
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2015 and 2030. However, a comprehensive public health program 
for HBV with full coverage of  infant vaccination, PMTCT, and 
high active case-finding and treatment with reduced-cost tenofovir 
covered in a national program could avert 2.1 million deaths by 
2030 and is likely to provide a positive ROI from an overall societal 
perspective (ROI = $1.57 per US dollar invested).
China was one of the first countries to initiate an invest-
ment case for viral hepatitis in 2015 and, given its high 
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Figure 3. A, Comparison of cost projections at status quo versus the comprehensive package. The left bar at each time point represents status quo costs, and the right 
bar represents the comprehensive package scenario. Costs are presented in USD (1 US$ = 6.2 RMB). B, Copayment scenarios for the comprehensive package. Note that the 
first panel is not to the same scale as subsequent panels. Costs are presented in USD (1 US$ = 6.2 RMB). The blue lines represent the status quo scenario, and red lines 
represent the comprehensive package of interventions. Abbreviations: Bn, billion; PMTCT, prevention of mother-to-child transmission; RMB, renminbi; USD, US dollars; Vacc, 
vaccination.
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burden of disease, is uniquely poised to make a significant 
global impact on the HBV epidemic. An increased effort in 
China alone could result in a 12% reduction of the total 17 
million predicted global HBV-related deaths between 2015 
and 2030 [16]. This approach proposes a unique framework 
for viral hepatitis strategy planning using a real-world case 
study and highlights how applied modeling can help initiate 
national dialog and inform policy change. Our study also 
highlighted how out-of-pocket patient costs will be high if 
patients had to pay the original price of tenofovir, particularly 
without reimbursement. Furthermore, achieving lower costs 
for tenofovir is key to there being a favorable ROI (Figure 4). 
In May 2016, the government of China successfully negoti-
ated the price reduction of tenofovir to less than one-third of 
its original price (from 1500 RMB [$237] to 490 RMB [$77] 
per month) [26, 27]. Concurrently, prices of generic entecavir, 
which was historically more expensive than tenofovir, fell to 
about 300 RMB per month. In February 2017, these 2 WHO-
recommended first-line anti-HBV medications were included 
in the national reimbursement drug list, allowing more pa-
tients access to the medications [28]; and in November 2017, 
China announced its national comprehensive action plan for 
viral hepatitis [28]. At the end of 2018, with patent expiry of 
tenofovir, the National Insurance Agency negotiated for cen-
tral pooled procurement supplying 11 provinces (comprising 
the main treatment burden) as a pilot, reducing the prices 
for both first-line medications to $30-35 per person-year. 
Extension of this pilot to the whole country in 2019 reduced 
prices further to $10 per person-year, effectively removing a 
major barrier in China to scale-up of treatment, which was 
the cost of medicines [25].
Previous epidemiological modeling analyses have examined 
the HBV epidemic in China [29, 30]; however, this study, to our 
knowledge, is the first analysis using an ROI approach to de-
velop an investment case for a comprehensive package of inter-
ventions for HBV. Its strengths include a collaborative process 
of stakeholder engagement, use of a high-quality epidemiolog-
ical model calibrated against nationwide seroprevalence data, 
consideration of the wider societal costs of premature death, as 
well as evaluating co-financing strategies. In the context of the 
subsequent adoption of the WHO global targets in 2016, such 
work has become essential to guide how countries might aim to 
achieve them.
Although the use of cost-effectiveness analyses (CEAs) pre-
dominates the recent health economic literature [31], the lack 
of clear data and consensus on cost-effectiveness thresholds 
and the indirect way in which CEAs respond to key questions 
about affordability and financial impact arguably limit their use 
when answering questions about budget expansion and value 
for money that a new investment would bring, especially in the 
context of low- and middle-income countries (LMICs). This in-
formed our decision to adopt an ROI approach for this study, 
which has been used in evaluating other public health inter-
ventions [32] and in the field of HIV [33, 34]. A review of ROI 
of public health interventions revealed wide ranges of returns 
from 1 to 14.3 and methodology was heterogeneous between 
studies [32].
The human capital method that we used to represent 
the cost of premature death is based on the theoretical and 
simplifying assumption that premature death means that the 
economy of the country forgoes potential future gross do-
mestic product contributions pertaining to that individual. 
This method has been used previously in other disease areas, 
including malaria [35] and cancer [36]. However, this ap-
proach considers only the market value of health. Other 
frameworks have been used to encompass broader aspects 
including the nonmarket value of a healthy life. One of these 
approaches includes the concept of “value of additional 
life-years” (VLYs), which has been used, along with Gross 
Domestic Product growth, in the full-income approach by 
the Global Health 2035 Lancet Commission in 2013 [37]. 
They estimated that the VLY to be an average of 2–3 times 
the per-person income in LMICs. Using such an alternative 
approach would place higher weight on the value of health 
interventions and therefore provide an even higher ROI than 
we have estimated in our study.
Although we have indicated the significant health gains, 
costs, and economic savings related to a scale-up of a compre-
hensive package of interventions against HBV, how these targets 
can be reached and how operationally, financially, or politically 
feasible this will be remain to be determined. First, there are 
Figure 4. Sensitivity analysis shows the effect of varying treatment costs and 
care costs on the likelihood that a comprehensive package will be cost saving. 
The current base-case estimate is represented by the point of intersection of both 
axes at 1, 1. The dashed white line represents the boundary (“frontier”) between 
whether the intervention will be cost saving or not. The shading to the left of this 
frontier (green and blue) indicates combinations of both scalers, which would mean 
that the intervention would be more cost-saving than the base-case estimate, and 
to the right (green to red) indicates fewer cost saving combinations.
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operational questions about how scale-up of case-finding to in-
crease diagnosis rates and treatment on such a large scale can 
be achieved, given the complexities of the Chinese healthcare 
system and provincial variation in implementation. Other than 
during pregnancy, systematic screening for HBV is not per-
formed in China. Innovative case-finding strategies have been 
used in other regions: for example, active case-finding for HBV 
has been shown to be feasible and cost-effective in other high-
endemic settings [38].
The economic projections, which have shown that case-
finding and treatment costs account for the majority of the 
overall comprehensive package, are critically dependent on price 
negotiations for the reduction of tenofovir therapy for HBV 
monoinfection to the price available in the HIV program, which, 
at the time of this study, was just 10% of the tenofovir price for 
HBV treatment. China’s economic position as an upper-middle-
income country, especially at a time of reduced donor funding 
internationally and the lack of any current global hepatitis-
funding mechanism, is likely to mean that expansion of a hep-
atitis program will need to be supported by domestic funding. 
In the HIV response, China has shown that migration from ex-
ternal to domestic funding has been possible, now funding more 
than 95% of its HIV response from domestic sources.
China-specific data were used where possible to parame-
terize the model. However, there are limitations of the avail-
able data. Despite the significant increase in the number of 
local population-based cancer registries in China (from 54 in 
2008, to 308 in 2014), many fail to meet quality standards for 
reporting [11]. We used 2012 cancer estimates reported to the 
International Agency for Research on Cancer (IARC), which 
only include data from registries with high reporting stand-
ards and therefore may not be representative of the country 
overall  [18]. Improvement in the validity and completeness 
of cancer registries is essential to provide more accurate pre-
dictions of the burden of HBV-related disease. There are also 
other factors which could affect the projections including the 
uncertainty in current estimates of the number of persons al-
ready diagnosed and in care, the impact of the recent relaxation 
of the 1-child policy [39] and the regional variation in costs of 
interventions.
Our study has shown that a comprehensive effort to address 
chronic HBV and related liver disease in China will help the 
country move closer to achievement of the recently adopted 
WHO hepatitis elimination goals and Sustainable Development 
Goals, provide economic returns on investment to society, and 
is likely to have a large impact on the global state of the hepatitis 
B epidemic. This study provides a strong policy framework that 
other countries can follow to tackle their HBV epidemic.
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